Analyst Conference Summaries

Biotechnology Investor Aids

Epizyme
EPZM

conference date: May 6, 2019 press release only

Epizyme As A Strategic Acquisition For Epigenetic Therapies by William Meyers [March 6, 2019 @ Seeking Alpha]

Epizyme Should Pop When Tazemetostat Hold Clears by William Meyers [August 23, 2018 @ Seeking Alpha]

Epizyme Partnership with Celgene [July 13, 2015 @ Seeking Alpha]

2019
Epizyme
Q1 2019
     
May 6, 2019      
2018
Epizyme
Q4 2018
May 8, 2018
Aug. 2, 2018
Nov. 2, 2018
Feb. 26, 2019
2017
May 8, 2017
Aug. 4, 2017
Nov. 1, 2017
Mar. 13, 2018  
2016
05/09/2016
08/08/2016
11/03/2016 
03/09/2017
2015
na
Q2 na
Q1
08/06/2015
11/09/2015
03/09/2016

Epizyme (EPZM) is a clinical-stage biotechnology pharmaceuticals comapny.

Epizyme web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 ISRG
 MCHP
 MYL.
 PLX
 REGN
 SGEN
 TTPH
 VBLT
 VSTM
 XLNX
 XLRN

 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2019 William P. Meyers